Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.

SentinelOne is making a major push this year around AI-powered SIEM, as well as cloud and data security, Channel Chief Brian ...

In today's digital landscape, data processing can occur either at centralized locations like data centers and on-premise ...

We recently published a list of 10 Best Software Infrastructure Stocks to Buy According to Analysts. In this article, we are ...

Sycomp A Technology Company, Inc., announced today that CRN®, a brand of The Channel Company, has named Sycomp to its Managed ...

In recent years, the broader technology sector has often been the driving force behind market growth. However, at the start ...

A Radical New Approach to Resolving the Arab-Israel Conflict. In early 2014, I hiked the Israel National Trail, an 800-mile ...

MIAMI, FL / ACCESS Newswire / February 10, 2025 / The recent executive order banning paper straws in the United States marks a pivotal shift in sustainability policy. While well-intentioned, the push ...

Delve into the recent cyberattacks on DeepSeek to expose key vulnerabilities in AI systems and their broader cybersecurity consequences.

When it comes to the SDLC of no-code development, organizations need to rethink how and where to embed security, focusing on phases where it can have the most impact.

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...